Reuters logo
4 months ago
BRIEF-Oncolytics Biotech announces registration pathway and clinical development plan
April 12, 2017 / 11:20 AM / 4 months ago

BRIEF-Oncolytics Biotech announces registration pathway and clinical development plan

April 12 (Reuters) - Oncolytics Biotech Inc -

* Announces registration pathway and clinical development plan

* Announced initial registration pathway and clinical development plan for reolysin, proprietary immuno-oncology viral agent

* Trial will recruit approximately 44 patients across up to six myeloma UK clinical trial network centres in UK

* Oncolytics and Celgene UK & Ireland are providing respective products for muk eleven

* Oncolytics is providing Reolysin and Celgene UK & Ireland is providing imnovid and revlimid Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below